Ionis Pharmaceuticals Inc.

Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo

BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells

San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue

Public Markets Preview: Will political uncertainty resolve in biotech’s favor or lead to economically damaging policy?

Genetic therapies compete in the same indications, as degraders come of age

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

Agency approves at least nine new therapies; adds new indications or patient populations to a dozen marketed drugs

Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development

Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s

Ionis’ first wholly owned product among three rare disease therapies up for approval. BMS expecting decision on subcutaneous Opdivo